Dr. James Crowe

Vanderbilt and the U.S. Army Development Command's Chemical Biological Center (DEVCOM CBC) signed a new educational partnership to advance national defense through innovative research in STEM fields. This collaboration aims to transform soldier safety and defense capabilities by integrating technologies and research into real-world solutions. Read More

Dr. James Crowe, Robert Carnahan and their colleagues in the Vanderbilt Vaccine Center won the Gold medal in the 2022 R&D 100 awards for their discovery and development of long-acting antibodies that protect against COVID-19. The discovery of these antibodies has led to the development of Evusheld, pre-exposure therapy to prevent COVID-19 for adults and children over 12 with compromised immune systems or a history of severe adverse reactions to a COVID-19 vaccine. Read More

The U.S. Food and Drug Administration granted emergency use authorization Dec. 8 to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination that protects against COVID-19, discovered last year at Vanderbilt University Medical Center. Read More

The remarkable success of the COVID-19 vaccines began in a Vanderbilt lab decades ago, with the groundbreaking research of alumnus Dr. Barney Graham. Read More